Attendee search 

Replace eye drops from FREEDOM drug releasing clear contact lens corneal bandage. The device has a 7 day wear time consistent with the standard of care recall after; cataract, LASIK surgery & corneal abrasion & non infectious Uveitis. Doctor puts device on and takes it off eliminating patient compliance problems with quicker healing with drug constantly treating the target tissue. 10 granted patents with FTO legal opinion. 10 mono and combo ophthalmic Dougs tested. Completed in vivo safety study. Letter and meeting being set with the US FDA for phase 1-2 clinical in January 2021.

Venn Biosciences innovates cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, unlocking glycoproteomics for Biomarker and Target Discovery.

Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.

Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.

Allakos is a public-traded clinical-stage biopharmaceutical company developing first-in-class antibody-based therapeutics to treat allergic and inflammatory diseases.

Bio ingredients supplier

Health analytics

Biotech

国际医疗器械研发及医疗培训

Mitochondria play a central role in metabolic diseases and cancer. Targeting mitochondria for therapeutic development provides a unique opportunity for the effective treatment of these devastating diseases, including nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and various cancers.

Mito Biopharma is a leading company in designing safe chemical mitochondrial uncouplers for
therapeutic development. We have developed a transformative and proven platform technology supporting lead development. Proof-of-concept studies demonstrated broad applications of the platform and superiority of mechanism of action. Therapeutic leads are protected by strong IP protection (worldwide composition-of-matter patent protection). The technology impacts high-value markets including NASH/T2D, Covid-19, and cancer.

We have IND- leads for NASH/T2D, Covid-19, and liver metastatic cancer. Our current focus is on a NASH lead. The company is seeking resources to support the NASH lead for IND and Phase I development, as well as pipeline development.

GenScript is a global biotech company (Stock Code: 1548. HK) with 4,000 employees worldwide. Founded in 2002, GenScript business encompass four major categories in synthetic biology, protein analysis and purification, biologics development and manufacturing, and cell therapy.